Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Mania and Antimanic Drugs: Overview

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Antiepileptic Drugs: GABAergic Pathway Potentiators

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...

Hepatic Encephalopathy

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Reliability and Feasibility Assessment of EldenCare: A Geriatric Clinical Decision Support System Pilot Study.

Hospital pharmacy·2026

Same author

Geriatric syndromes, comorbidities, and polypharmacy: Determinants of health-related quality of life in hospitalized older adults in South India.

Geriatric nursing (New York, N.Y.)·2026

Same author

Adult Immunisation in a South Indian Tertiary Care Hospital: Who Benefits, What's Safe, and What Holds Us Back?

Journal of primary care & community health·2025

Same author

Multi-Criteria Assessment of Potentially Inappropriate Medications in Hospitalized Indian Older Adults: Comparing BEERS, STOPP, and FORTA.

Journal of applied gerontology : the official journal of the Southern Gerontological Society·2025

Same author

Randomized controlled trial to assess medication adherence and health-related quality of life through a collaborative pharmacist-psychiatrist approach to patient education in patients with depression in India.

Frontiers in psychiatry·2025

Same author

Management and prognosis of acute Emamectin Benzoate poisoning in a human.

Toxicology reports·2024

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents

Published on: September 1, 2011

Valproic acid-induced abnormal behavior.

Nanjangud Chandrashekar Nagalakshmi¹, Madhan Ramesh, Gurumurthy Parthasarathi

¹Department of Pharmacy Practice, J.S.S. College of Pharmacy, Mysore, India.

Indian Journal of Psychiatry

|February 23, 2010

Summary

Valproic acid, used for epilepsy, can rarely cause abnormal behavior in patients. Discontinuing this medication led to the patient's full recovery, highlighting the need for vigilance regarding its behavioral side effects.

Keywords:

Adverse drug reaction behavior valproic acid

More Related Videos

Developing a Rat Model for Bipolar Disorder

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Related Experiment Videos

Last Updated: Jun 16, 2026

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents

Published on: September 1, 2011

Developing a Rat Model for Bipolar Disorder

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Area of Science:

Neurology
Psychiatry

Background:

Valproic acid is a common antiepileptic drug.
Behavioral disturbances are a rare but possible side effect.

Purpose of the Study:

To report a case of valproic acid-induced behavioral disturbances.
To emphasize the importance of monitoring for adverse behavioral effects.

Main Methods:

A case study of a 12-year-old female with epilepsy.
Observation of behavioral changes during valproic acid treatment.
Discontinuation of valproic acid and subsequent recovery.

Main Results:

The patient developed abnormal behavior on valproic acid.
Behavioral disturbances resolved after valproic acid withdrawal.
Causality was assessed as 'possible' for valproic acid.

Conclusions:

Behavioral disturbances associated with valproic acid are rare and reversible.
Vigilance for abnormal behavioral effects is crucial in patients on valproic acid.
Carbamazepine was used as an alternative antiepileptic medication.